Patient, donor, and transplant characteristics
| Characteristic . | Value . |
|---|---|
| N | 43 |
| Patient age, years | |
| Median | 38 |
| Range | (3-66) |
| <18 years, n | 5 |
| Patient sex, female, n (%) | 16 (37) |
| Disease and status at transplant, n (%) | |
| AML | 17 (40) |
| CR1 | 14 |
| CR2 | 3 |
| MRD | 5 |
| ALL | 13 (30) |
| CR1 | 8 |
| CR2 | 4 |
| CR3 | 1 |
| MRD | 5 |
| MDS | 9 (21) |
| >5% blasts | 4 |
| CML | 3 (7) |
| CP | 1 |
| AP | 2 |
| NHL | 1 (2) |
| Disease status at transplant, n (%) | |
| Remission without MRD | 22 (51) |
| MRD or active disease | 21 (49) |
| Preparative regimen, n (%) | |
| Fludarabine/targeted busulfan | 25 (58) |
| Total body irradiation (≥12 Gy) | 18 (42) |
| Donor type, n (%) | |
| HLA-matched related | 12 (28) |
| HLA-matched unrelated | 30 (70) |
| HLA-mismatched unrelated | 1 (2) |
| Donor/recipient sex, n (female → male) | 11 |
| CMV serology, n | |
| Donor−/recipient− | 13 |
| Donor+/recipient− | 6 |
| Donor+/recipient+ | 12 |
| Donor−/recipient+ | 12 |
| Cell dose infused | |
| TNC × 109/kg | |
| Median | 1.0 |
| Range | 0.34-2.3 |
| CD34 × 106/kg | |
| Median | 8.25 |
| Range | 2.4-25 |
| CD3 × 108/kg | |
| Median | 2.8 |
| Range | 1.3-7.4 |
| Characteristic . | Value . |
|---|---|
| N | 43 |
| Patient age, years | |
| Median | 38 |
| Range | (3-66) |
| <18 years, n | 5 |
| Patient sex, female, n (%) | 16 (37) |
| Disease and status at transplant, n (%) | |
| AML | 17 (40) |
| CR1 | 14 |
| CR2 | 3 |
| MRD | 5 |
| ALL | 13 (30) |
| CR1 | 8 |
| CR2 | 4 |
| CR3 | 1 |
| MRD | 5 |
| MDS | 9 (21) |
| >5% blasts | 4 |
| CML | 3 (7) |
| CP | 1 |
| AP | 2 |
| NHL | 1 (2) |
| Disease status at transplant, n (%) | |
| Remission without MRD | 22 (51) |
| MRD or active disease | 21 (49) |
| Preparative regimen, n (%) | |
| Fludarabine/targeted busulfan | 25 (58) |
| Total body irradiation (≥12 Gy) | 18 (42) |
| Donor type, n (%) | |
| HLA-matched related | 12 (28) |
| HLA-matched unrelated | 30 (70) |
| HLA-mismatched unrelated | 1 (2) |
| Donor/recipient sex, n (female → male) | 11 |
| CMV serology, n | |
| Donor−/recipient− | 13 |
| Donor+/recipient− | 6 |
| Donor+/recipient+ | 12 |
| Donor−/recipient+ | 12 |
| Cell dose infused | |
| TNC × 109/kg | |
| Median | 1.0 |
| Range | 0.34-2.3 |
| CD34 × 106/kg | |
| Median | 8.25 |
| Range | 2.4-25 |
| CD3 × 108/kg | |
| Median | 2.8 |
| Range | 1.3-7.4 |
AP, accelerated phase; CMV, cytomegalovirus; CP, chronic phase; NHL, non-Hodgkin lymphoma; TNC, total nucleated cells.